Medsafe Investigates Estradot Oestrogen Patches
- New Zealand's regulatory authority, Medsafe, is facing calls for a thorough investigation into reports of faulty hormone replacement therapy (HRT) patches.
- Crystal, a patient experiencing perimenopause, shared her experience and concerns after connecting with others in an online support group.
- These symptoms can include hot flashes, night sweats, mood swings, sleep disturbances, and vaginal dryness. The failure of the patches to work as intended can significantly impact a...
Okay, here’s a draft article based on the provided text, aiming for the specified quality and incorporating the requested elements.I’ve expanded it with context where possible, and flagged areas where further research woudl be beneficial. I’ve also included the requested HTML structure.
“`html
Medsafe Investigates Reports of Faulty Menopause Patches, Raising Patient Concerns
Table of Contents
Published: October 21, 2023 (Updated as needed)
What Happened?
New Zealand’s regulatory authority, Medsafe, is facing calls for a thorough investigation into reports of faulty hormone replacement therapy (HRT) patches. patients are reporting that the patches are not adhering to the skin properly or are failing to deliver the medication effectively, leading to a return of perimenopause symptoms.
Crystal, a patient experiencing perimenopause, shared her experience and concerns after connecting with others in an online support group. She and others have identified potential links between the issues and specific batch numbers of the medication.
Reported Issues with the Patches
Patients are reporting two primary problems with the HRT patches:
- Poor Adhesion: The patches are not sticking to the skin as they should, potentially reducing the amount of medication absorbed.
- ineffective Medication Delivery: Even when the patches adhere, some users report that they are not receiving the expected therapeutic effect, with symptoms of perimenopause returning.
These symptoms can include hot flashes, night sweats, mood swings, sleep disturbances, and vaginal dryness. The failure of the patches to work as intended can significantly impact a patient’s quality of life.
Crystal specifically noted experiencing relief from her symptoms when the patches were functioning correctly,making the current situation especially distressing.
Patient Concerns and Calls for Action
Crystal expressed frustration with the pace of Medsafe’s response, contrasting it with the potential public outcry if a similar issue affected a medication like Viagra. She highlighted the serious mental health risks associated with untreated perimenopause, stating that the anxiety and depression can lead to suicidal ideation. “Other people need to know this because the anxiety and depression that comes with perimenopause can lead to suicidal ideation, so this is peoples’ lives at stake,” she said.
She is advocating for two specific changes:
- Removal of Funding Limits: Crystal believes that current funding restrictions on HRT patches may discourage patients from seeking option treatments if these patches are unreliable.
- substantial Investigation: A extensive investigation by Medsafe to determine the cause of the patch failures and ensure the safety and efficacy of the medication.
Medsafe’s Response
Medsafe reportedly provided Crystal with a response to her concerns after she sent an email a week prior to the report (approximately October 14, 2023). The specific details of Medsafe’s response were not included in the provided text and would require further investigation.Medsafe’s website is the official source for information on medication safety in New Zealand.